De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years [J]. Rev Med Virol, 2009, 19(5):287-299.
[2]
Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance [J]. N Engl J Med, 2011, 365(7):637-646.
[3]
Liao L, Xing H, Dong Y, et al. Surveys of transmitted HIV drug resistance in 7 geographic Regions in China, 2008-2009 [J]. Clin Infect Dis, 2012, 54(S4):S320-323.
[4]
Liu S, Jia MM, Zheng Y, et al. CTL responses directed against accessory protein Vpr in HIV-1 clade B’ infected individuals [J]. China Trop Med, 2012, 12(7):779-782. (In Chinese)
Jiang S, Xing H, Si X, et al. Polymorphism of the protease and reverse transcriptase and drug resistance mutation patterns of HIV-1 subtype B prevailing in China [J]. J Acquir Immune Defic Syndr, 2006, 42(4):512-514.
[7]
Sun JP, Ma LY, Huang JH, et al. Detection of phenotypic drug-resistance of HIV-1 strains by TZM-b1 cell lines in China [J]. Chin J AIDS STD, 2008,14(5):439-441. (In Chinese)
Taylor BS, Sobieszczyk ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity [J]. N Engl J Med, 2008,358(15):1590-1602.
[10]
Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010 [J]. Top HIV Med, 2010, 18(5):156-163.
[11]
Santos AF, Tebit DM, Lalonde MS, et al. Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility [J]. Antimicrob Agents Chemother, 2012, 56(5):2719-2725.
[12]
Quinones-Mateu ME, Moore-Dudley DM, Jegede O, et al. Viral drug resistance and fitness [J]. Adv Pharmacol, 2008, 56:257-296.
[13]
Svicher V, Sing T, Santoro MM, et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors [J]. J Virol. 2006, 80(14):7186-7198.
